Add-on perampanel in Lance–Adams syndrome

Abstract Perampanel (PER) is the first-in-class selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for patients with partial-onset and primary generalized tonic–clonic sei...

Full description

Saved in:
Bibliographic Details
Published in:Epilepsy & behavior case reports 2016-01, Vol.6, p.28-29
Main Authors: Steinhoff, Bernhard J, Bacher, Matthias, Kurth, Christoph, Staack, Anke M, Kornmeier, Reinhold
Format: Article
Language:English
Subjects:
Case Report
Efficacy
Lance–Adams syndrome
Myoclonus
Neurology
Perampanel
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Perampanel (PER) is the first-in-class selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for patients with partial-onset and primary generalized tonic–clonic seizures. A positive effect was reported in some patients with epileptic myoclonic jerks in idiopathic generalized epilepsy and in progressive myoclonic epilepsy. We treated a male patient with posthypoxic nonepileptic myoclonus (Lance–Adams syndrome) with add-on PER and achieved an almost complete cessation of jerks. This effect was reproducible and, therefore, we suggest that it might be worth trying PER in comparable cases.
ISSN:2213-3232
2213-3232
DOI:10.1016/j.ebcr.2016.05.001